Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 23, 2024--
Source: eagletribune.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Linkedin Juvena. Real-time updates on events, politics, business and more.